An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period. The results from early clinical trials were presented by Novo ...

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of ...

These medications typically help you control your appetite or help your body respond to the foods you eat. However, these ...

more people are turning to old-school weight loss drugs such as Qsymia and Contrave, which come in pill form but also include ...

The weight-loss drug Contrave carries a black box warning about suicidal thinking, and another obesity medicine, Qsymia, carries a warning telling patients to stop taking it if they experience ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill.

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

It outperformed Orexigen's Mysimba/Contrave weight loss drug, where around a quarter of patients in a phase 3 trial achieved the target. Semaglutide came out top of the analysis, with 63% of ...

The U.S. Food and Drug Administration (FDA ... stop the medication and help you choose a different weight loss treatment. Contrave is a twice-daily medication approved only for adults meeting ...